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Approximately 12% of all human cancers are caused by oncoviruses. Human viral oncogenesis is complex,
and only a small percentage of the infected individuals develop cancer, often many years to decades after
the initial infection. This reflects the multistep nature of viral oncogenesis, host genetic variability, and the
fact that viruses contribute to only a portion of the oncogenic events. In this review, the Hallmarks of
Cancer framework of Hanahan and Weinberg (2000 and 2011) is used to dissect the viral, host, and environ-
mental cofactors that contribute to the biology of multistep oncogenesis mediated by established human
oncoviruses. The viruses discussed include Epstein-Barr virus (EBV), high-risk human papillomaviruses
(HPVs), hepatitis B and C viruses (HBV and HCV, respectively), human T cell lymphotropic virus-1
(HTLV-1), and Kaposi’s sarcoma herpesvirus (KSHV).Introduction
Approximately 12% of human cancers worldwide are caused by
oncovirus infection, with more than 80% of cases occurring in
the developing world (Bouvard et al., 2009; Boyle and Levin,
2008; de Martel et al., 2012). Despite their prevalence, public
health importance, and suitability for immunoprophylaxis and
targeted therapies, understanding and managing virus-induced
cancers still faces formidable challenges. This is due to limited
animal models of disease, the disparate nature of viral-induced
cancers, the very distinct types of viruses that cause them,
and the complex nature of the virus-host cell interactions leading
to cancer development (zur Hausen, 2009).
Human viral oncogenesis has common traits (Bouvard et al.,
2009; zur Hausen, 2009): (1) oncoviruses are necessary but
not sufficient for cancer development, so cancer incidence is
much lower than virus prevalence in human populations; (2) viral
cancers appear in the context of persistent infections and occur
many years to decades after acute infection; (3) the immune
system can play a deleterious or a protective role, with some
human virus-associated cancers increasing with immuno-
suppression and others appearing in the context of chronic
inflammation. The Hallmarks of Cancer framework developed
byWeinberg and Hanahan allows the dissection of themalignant
phenotype into specific cellular capabilities that are acquired
during the carcinogenic process (Hanahan and Weinberg,
2000, 2011). Each cancer ‘‘hallmark’’ represents a biological
consequence of oncogenic alteration(s) that underlies the
tumor’s phenotypic characteristics (Figure 1). For instance,
oncogenic mutations that constitutively activate RAS, a potent
regulator of the MAPK and PI3K-AKT-mTOR cascades, convey
proliferation, survival, angiogenesis, and metabolic-related
hallmarks to a tumor cell. Mutations that inactivate the tumor
suppressor gene p53 (TP53), a DNA damage-induced activator266 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.of growth inhibition and apoptosis, enables uncontrolled growth
and genetic instability hallmarks. The Hallmarks of Cancer
framework also helps to explain the multistep nature of human
carcinogenesis (Vogelstein and Kinzler, 1993), which outlines
the time dependence for the development of a cancer that re-
quires the progressive acquisition of all necessary cellular hall-
marks that constitute a malignant phenotype. This results from
the accumulation of somatic oncogenic alterations, sometimes
referred to as ‘‘oncogenic hits,’’ caused by spontaneous muta-
tions or mutations as a consequence of exposure to environ-
mental carcinogenic factors in the context of the genetic back-
ground of the host and the selective pressures imposed by the
tissue microenvironment (Hanahan and Weinberg, 2000, 2011).
The cancer hallmark model, therefore, is also a powerful tool to
organize and understand the process of human virus-associated
carcinogenesis. Early studies with acutely transforming viruses
suggested that viruses are sufficient to cause cancer because
they carry powerful oncogenes. Human oncoviruses, however,
appear to be necessary but not sufficient to cause cancer and
are rarely fully oncogenic per se. This indicates that within the
context of multistep carcinogenesis, viral infection provides
only a subset of the required oncogenic hits. Additional cofactors
such as immunosuppression, chronic inflammation, or environ-
mental mutagens are generally necessary for malignant transfor-
mation (Bouvard et al., 2009; zur Hausen, 2009). The Cancer
Hallmarks framework helps to discern the contribution to the
oncogenic process of viral genes, of the host response to the
infection, and of acquired somatic mutations. In this review, we
will analyze oncogenesis mechanisms and identify host and
environmental cofactors contributing to full development of ma-
lignancy for each of the major human viruses defined in the last
IARC report as Group 1 Biological carcinogenic agents for which
there is ‘‘sufficient evidence of carcinogenicity in humans’’
Figure 1. Cancer Hallmarks Activation by
Human Oncoviruses
(A) Oncogenic risks of strategies for viral replication
and persistence. Many of the molecular
mechanisms deployed by human oncoviruses
to maximize replication and persistence imply
hijacking the host cell’s signaling machinery,
leading to acquisition of cancer hallmarks. The
main strategies for viral replication and persistence
are listed (on the left). Below each of them are
the cellular responses that the virus induces
to undertake each of these strategies. Virally
induced cell responses are color coded according
to the Hallmarks of Cancer to which they corre-
spond (on the right). The picture on the right is a
reproduction from the review by Hanahan and
Weinberg (2011).
(B) Activation of oncogenic pathways by viral
oncogenes leads to acquisition of cancer hall-
marks by the infected cell. The table shows
established viral oncogenes, the main cellular
pathways they regulate, and the cancer hallmarks
they can potentially induce. Hallmarks are color
coded as the wheel in (A). Data from tumor
models were given preference. HBV and HCV are
potentially able to activate all hallmarks depending
on HCC stage as described in the text and
Figure 4.
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hepatitis C virus (HCV), Epstein-Barr virus (EBV), high-risk hu-
man papillomaviruses (HPVs), human T cell lymphotropic virus-
1 (HTLV-1), HIV, and Kaposi’s sarcoma herpesvirus (KSHV).
Since HIV acts as a cofactor of AIDS-defining cancers that are
associated with EBV and KSHV, it will be discussed within the
context of these other viruses.
Oncovirus Replication and Persistence Strategies
Involve Activation of Cancer-Causing Pathways
Coevolution of oncoviruses and their hosts is a fight for survival.
Hosts evolved immune defenses against viral infections, while
viruses have coevolved to evade host immune response and
other host restrictions. Human oncogenic viruses rely on per-
sistence to disseminate and thus deploy powerful immune
evasion programs to establish long-term infections. As part
of their replication and immune evasion strategies, humanCell Host & Microbeoncoviruses have evolved powerful anti-
apoptotic and proliferative programs that
can directly induce cancer hallmarks in
the infected cell (Figure 1A) (Moore and
Chang, 2010; zur Hausen, 2009). When
these viruses overcome the ability of
the host to maintain homeostasis, they
trigger cellular changes ultimately leading
to cancer. The underlying mechanisms
include:
(1) Signaling mimicry: Viruses encode
proteins that are able to subvert, in
a dominant manner, host-signaling
mechanisms that regulate cell
growth and survival (Figures 1A
and 1B). These are generally thesame signaling pathways that, when deregulated, provide
antiapoptotic and antiproliferative hallmark capabilities in
nonviral cancers (Figure 1B).
(2) Effects on the DNA damage response (DDR): Recognition
of viral genomes or replicative intermediates by the host
leads to induction of DDR, which many oncoviruses
need for their replication. As a consequence, however,
host cells acquire genetic instability, which increases their
mutation rate and accelerates acquisition of oncogenic
host chromosomal alterations (McFadden and Luftig,
2013) (also see review in this issue by Weitzman and
Weitzman [2014]).
(3) Chronic inflammatory responses to persistent viral infec-
tion: inflammation drives reactive oxygen species (ROS)
generation that promotes the acquisition of mutations.
This is observed in chronic HBV and HCV infections,
where virus-triggered inflammatory responses lead to15, March 12, 2014 ª2014 Elsevier Inc. 267
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carcinoma (Arzumanyan et al., 2013).Epstein-Barr Virus: Posing Oncogenic Dangers by
Adopting a B Cell Lifestyle
EBV is an oncogenic gamma-1 herpesvirus implicated in several
lymphoid malignancies, including several B, T, and NK cell lym-
phomas and epithelial carcinomas (Cesarman and Mesri, 2007;
Kutok and Wang, 2006). EBV mimics B cell proliferative and
survival signaling, allowing it to replicate its genome while
remaining latent and immune-silent in the host B cells, thus es-
tablishing lifelong persistence, which favors its transmission (Ce-
sarman and Mesri, 2007; Young and Rickinson, 2004). In certain
scenarios the B cell growth-promoting abilities of EBV infection
have oncogenic consequences. Different transcription programs
are established to maintain a lifelong EBV infection. Since the
same transcriptional programs are found in EBV lymphomas
and cancers, the patterns of latency determining which EBV
genes are expressed are key for understanding the role of EBV
infection in inducing cancer hallmarks (Cesarman and Mesri,
2007; Kutok and Wang, 2006). When EBV first infects a naive B
cell, it deploys the growth program or latency III (Lat III) pattern,
whereby EBV expresses EBNA1–EBNA 6, as well as LMP1,
LMP2A, and LMP2B. This pattern of expression forces infected
cells to become proliferating B cells, allowing replication of
EBV episomes. Latency III is, however, very immunogenic, and
cells displaying this pattern are eliminated by cytotoxic T lym-
phocytes (CTLs). This drives positive selection of infected B cells
that are able to switch to a ‘‘default program’’ or latency II (Lat II)
pattern, expressing only EBNA1, LMP1, and LMP2A of subdom-
inant immunogenicity. In these cells, the ability of LMP1 and
LMP2A to mimic CD40 and IgG receptor signaling drive B cells
to differentiate into resting memory B cells (Thorley-Lawson,
2001; Young and Rickinson, 2004). These infected cells in turn
can switch to either of two immunologically silent latency pro-
grams. A Latency 0 (Lat 0) pattern, where only EBV-encoded
RNAs (EBER 1 and 2) are expressed, can be observed in resting
memory B cells where no viral proteins need to be expressed
(Thorley-Lawson, 2001). EBV-infected dividing memory B cells
need to switch to the EBNA1-only program/Latency I (Lat I)
pattern, whereby EBNA1 allows the EBV episome to be segre-
gated and retained in dividing B cells.
Molecular Mechanisms of EBV Oncogenesis: Cancer
Hallmarks Activation at Every Stage
The latency patterns of EBV are associated with specific lym-
phoma subtypes. EBV latent gene expression can be linked to
specific molecular and oncogenic cancer hallmarks of the
lymphoid malignancies depicted in Figure 2.
Latency I: Burkitt’s Lymphoma. EBNA1 function in latency is to
leash EBV episomes to the host chromosome, thus allowing their
retention and segregation during cell division. In addition,
EBNA1 is essential for lymphoma survival by preventing cell
death (Kirchmaier and Sugden, 1997). It may also increase
genomic instability by regulating RAG-1 and RAG-2 (Tsimbouri
et al., 2002) and increasing ROS. EBERs are noncoding RNAs
with abundant dsRNA pairing that trigger Toll-like receptor
TLR-3 leading to upregulation of IFN and proinflammatory cyto-
kines (Iwakiri et al., 2009).Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.Latency II: Hodgkin’s Disease and Nasopharyngeal Carci-
noma. In addition to the Lat I genes, this pattern includes expres-
sion of LMP1 and LMP2A, two EBV oncogenes that mimic key
survival and proliferative signals in B cells. LMP1 mimics a
constitutively active CD40 receptor (Mosialos et al., 1995).
LMP1 constitutively aggregates and recruits TRAFs and TRADD
leading to activation of NF-kB, a key transcription factor in viral
and nonviral lymphomagenesis (Mosialos et al., 1995). NF-kB
promotes cell survival by upregulation of the antiapoptotic
proteins A20 and BCL-2 and a variety of cellular genes related
to B cell proliferation and malignancy. They include the inflam-
matory-related genes IL-6, ICAM-1, LFA-3, CD40, EBI3, and
the matrix metalloproteinase-9, which can contribute to invasion
and metastasis. LMP1 may promote genetic instability through
telomerase activation via JNK and inhibition of the DDR leading
to micronuclei formation and chromosomal aberrations. LMP2A
is a 12 transmembrane domain protein able to mimic signaling
via activated B cell Ig receptors (Merchant et al., 2000). Its tail
contains phosphotyrosines that recruit cytoplasmic tyrosine
kinases such as Lyn via the SH2 domain, as well as ITAM motifs
homologous to the gamma-chain Ig receptor that can recruit
SYK kinase. Mimicking a crosslinked Ig receptor, LMP2A
signaling promotes mature B cell differentiation, survival, and
cell growth in absence of Ig receptor expression by activating
the PI3K-AKT pathway and pathways mediating cell mobility
and invasion (Merchant et al., 2000; Portis and Longnecker,
2004; Young and Rickinson, 2004).
Latency III: Most AIDS-Associated Non-Hodgkin’s Lym-
phomas and Posttransplant Lymphoproliferative Disorder. In
addition to Latency II’s EBNA1, LMP1, and LMP2A, this pattern
expresses a full oncogenic component of nuclear proteins
EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNALP, and the EBV
microRNAs. EBNA2 is a nuclear phosphoprotein that mimics
cleaved Notch and can associate with RBP-Jk to activate the
expression of Notch target genes (Ho¨felmayr et al., 2001).
Deregulated Notch signaling is known to drive nonviral lymphoid
malignancies. EBNA2 is able to deregulate expression of MYC,
further increasing cell proliferation by upregulating cyclin Ds
and E and by downregulating CDK2 inhibitors such as p21CIP1
and p27KIP1 (Kaiser et al., 1999). EBNA3C is also able to target
cell-cycle checkpoints by engaging the SCF (skp, Cullin,
F-Box) ubiquitin ligase complex that may target the retinoblas-
toma tumor suppressor for proteasomal degradation (Knight
et al., 2005).
Lytic Cycle Genes. Increasing evidence suggests that expres-
sion of lytic cycle genes (Kutok and Wang, 2006), particularly
early lytic genes and those encoding homologs of BCL-2
(BALF1), IL-10 (BCRF1), and a decoy for the M-CSF receptor
(BARF1), may have oncogenic consequences (Thompson and
Kurzrock, 2004). In a recent study of 700 EBV-immortalized
lymphoblastoid cell lines that were characterized for host and
viral transcriptome and epigenomes, viral lytic genes were coex-
pressedwith cellular cancer-associated pathways, strongly sug-
gesting that EBV lytic genes play a role in oncogenesis (Arvey
et al., 2012).
EBV-Encoded miRNA. EBV encodes two clusters of miRNA,
one adjacent to the BHRF1 gene and the other with the BART
transcript. They are differentially expressed in epithelial and B
cell lineages and can play roles in oncogenesis by targeting
Figure 2. Hallmarks of Cancer Analysis of EBV-Mediated Lymphomagenesis
When EBV infects B cells, it establishes a ‘‘growth program’’ or Latency III pattern, which expresses EBV proteins with sufficient oncogenic potential to cause
immortalization in vitro and B cell growth and differentiation in vivo. However, this program is highly immunogenic due to EBNA-2,3 protein expression. The
resulting immune pressure from cytotoxic T lymphocytes (CTL) promotes in infected cells a switch to the ‘‘default program’’ (see text), and then to the Latency
(Lat) I program, which is not immunogenic and not oncogenic since only EBNA1 and EBERs are expressed. In immunosuppressed and AIDS patients, Lat III cells
can thrive and lead to PTLD or AIDS-NHL, where host somatic mutations such as BCL-6 overexpression, p53mutation, or RASmutations further contribute to all
the hallmarks for lymphomagenesis. In malaria-affected regions, P. falciparum-induced B cell proliferation favors the occurrence of 8:14 translocations that lead
to MYC overexpression. MYC expression with additional host somatic mutations, such as p53 inactivation, may complement the oncogenicity of Lat I pattern,
leading to Burkitt’s lymphomagenesis. Viral genes are depicted in red and host genes in black. The figure is not a strict representation of experimental data but
rather a compilation of published information analyzed in the context of the Hallmarks of Cancer. Genes chosen for hallmarks activation represent one of the
available examples and are based on published data with preference for tumor-relevant systems where available. Filled portions within the hallmark pie are used
to represent stronger or well-documented hallmark activation. Empty portions represent weaker effects or lack of activation/evidence. See text for explanations
and references.
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apoptosis (Vereide et al., 2013; Zhu et al., 2013).
EBV-Mediated Lymphomagenesis
The Lat II and Lat III patterns are oncogenic in B and epithelial
cells. However, these patterns of EBV gene expression elicit an
immune response because EBNA proteins, except EBNA1, are
immunogenic (Cesarman and Mesri, 2007). In immunocompe-
tent individuals, Lat III B cells are eliminated by the immune
system (Thorley-Lawson, 2001; Young and Rickinson, 2004)
(Figure 2). Thus, lymphomas with EBV Lat III will only develop
in immunodeficient individuals, while EBV lymphomas and can-
cers in immunocompetent hosts will display Lat I or II patterns(Cesarman and Mesri, 2007; Kutok and Wang, 2006). Neverthe-
less, development of all EBV-induced cancers requires cofac-
tors. For Lat I cancers, cofactors facilitate the acquisition of
further oncogenic hits, either by host somatic mutation or by
another virus infection. In BL, Lat I (with sporadic LMP2A expres-
sion) is found in the 90%of the cases with a t(8;14) chromosomal
translocation that places the MYC gene under the control of
immunoglobulin heavy-chain genes enhancer (Cesarman and
Mesri, 2007; Kutok and Wang, 2006). The endemicity of BL is
coincident with theMalaria belt in Africa, and Plasmodium falcip-
arum infection is a cofactor for development of BL (Rochford
et al., 2005). Plasmodium infection prompts polyclonal B cellCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 269
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lihood of chromosomal translocations that cause aberrant MYC
expression. Such translocations may allow a Lat III/II-infected B
cell to switch to Lat I without losing the ability to proliferate. The
lymphomagenic gene MYC can complement Lat I oncogenic
deficiencies, since it drives cell proliferation, metabolic reprog-
ramming, and oxidative stress (Figure 2). Primary effusion lym-
phoma (PEL) is another example. In this case the oncogenic
complement of EBV Lat I is latent KSHV infection with a variable
percentage of lytic replication. KSHV latent genes are potent
regulators of cell proliferation and survival that could comple-
ment the limited oncogenicity of EBV Lat I (reviewed in Cesarman
and Mesri, 2007) (see also section on KSHV), while lytic gene
expression may account for some key phenotypic characteris-
tics of PEL such as angiogenicity and permeability promoted
by VEGF.
The most important cofactor for development of malignancies
displaying Lat III expression patterns is immunosuppression,
which is generally found in posttransplant lymphoproliferative
disorder (PTLD) and in non-Hodgkin’s lymphomas (NHLs) asso-
ciated with HIV/AIDS (Figure 2). In PTLD, transplant-related
immunosuppression allows immunogenic Lat III-infected cells
to proliferate and, in time, acquire host somatic oncogenic alter-
ations such as BCL-6 overexpression and mutations, A20 over-
expression, and p53 inactivation (Cesarman and Mesri, 2006;
Kutok and Wang, 2006). AIDS-NHL is a complex group of can-
cers that prior to the implementation of antiretroviral therapy
(ART) affected between 4% and 10% of HIV/AIDS patients.
The incidence of at least some subsets appears to be decreasing
with ART. In addition to immunosuppression and similar host
oncogenic alterations to PTLD, other cofactors such as HIV pro-
teins, chronic antigenic stimulation, and cytokine dysregulation
may play a role (Casper, 2011; Kutok and Wang, 2006). Finally,
Latency II pattern is expressed in two EBV-associated malig-
nancies: Hodgkin’s disease and nasopharyngeal carcinoma.
Hodgkin’s disease is associated with EBV infection in approxi-
mately 40%–50% of cases, depending on the geographical
location. Hodgkin’s-Reed-Sternberg (HRS) cells are a minority
of transformed B cells that are supporting normal lymphoid
proliferation in a paracrine/cytokine-driven manner. They are
derived from germinal B cells destined to undergo apoptosis
that are protected by EBV Lat II genes LMP1 and LMP2 (Ku¨p-
pers, 2009). Nasopharyngeal carcinomas are epithelial cancers
that also express Lat II patterns, where LMP1 and LMP2A
play several well-established roles in epithelial carcinogenesis
(Raab-Traub, 2002). The endemicity of nasopharyngeal carci-
noma is strongly suggestive of environmental cofactors. In
southern China, one of these cofactors may be the consumption
of salted fish.
Human Papillomaviruses: Small Viruses that Pack a Big
Punch
Approximately 5% of all human cancers worldwide are caused
by HPVs. Papillomaviridae are a large family of epitheliotropic
nonenveloped viruses with double-stranded circular 8 kB
DNA genomes. Of the 150 HPV genotypes that have been
characterized, a small group of ‘‘high-risk’’ alpha HPVs that
specifically infect mucosal epithelial cells cause almost all cases
of cervical carcinoma, a leading cause of cancer death in270 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.women, as well as other anogenital cancers including vulvar,
vaginal, penile, and anal carcinomas and a fraction of oral carci-
nomas. In contrast, low-risk alpha HPVs cause benign genital
warts. HPV16 and HPV18 are the most abundant high-risk and
HPV6 and HPV11 are the most frequent low-risk HPVs.
HPVs infect basal epithelial cells where viral genomes are
persistently maintained as low-copy-number episomes. Viral
genome amplification, late gene expression, and viral progeny
synthesis are confined to terminally differentiated layers of the
infected epithelium. Since terminally differentiated epithelial cells
are growth arrested and do not express DNA replication en-
zymes needed for viral genome replication, HPVs have evolved
to retain differentiated keratinocytes into a DNA synthesis-
competent state. The strategies that high-risk alpha HPVs have
developed to accomplish this have the potential to trigger cancer
development (McLaughlin-Drubin et al., 2012; Moody and Lai-
mins, 2010).
While the oncogenicity of high-risk HPVs represent conse-
quences of their replication strategies, HPV-associated cancers
generally represent ‘‘nonproductive infections,’’ where some
viral proteins are expressed but no infectious viral progeny is
produced. Many high-risk HPV-positive cervical carcinomas
contain integrated HPV sequences. Integration frequently oc-
curs at common fragile sites of the human genome and in
some cases can lead to increased expression of cellular proto-
oncogenes such as MYC (Du¨rst et al., 1987). Integration retains
the integrity of the long control region (LCR), as well as the E6
and E7 coding region, while other viral proteins, including the
E2 transcriptional repressor that negatively regulates E6/E7
expression, are no longer expressed, causing dysregulated E6/
E7 expression (Figure 3A). In cases where HPV episomes are
maintained in cancers, E6/E7 expression may be dysregulated
due to epigenetic alterations of the viral genome.
Molecular Mechanisms of HPV Carcinogenesis: HPV
Oncogenes Activate Multiple Cancer Hallmarks
High-risk HPV E6 and E7 genes encode potent oncoproteins,
and E5 is also oncogenic. HPV-positive cervical carcinoma lines
are ‘‘addicted’’ to E6/E7 expression, and cellular regulatory
pathways that are targeted by E6 and E7 are rendered
‘‘dormant’’ but remain intrinsically functional (Goodwin et al.,
2000). The following discussion summarizes some of the biolog-
ical activities of HPV E6, E7, and E5 proteins in the context of
the ‘‘hallmarks of cancer’’ framework (Figure 3B). The readers
are referred to other review articles for more comprehensive
summaries of the biological and biochemical activities of HPV
proteins (DiMaio and Petti, 2013; Roman and Munger, 2013;
Vande Pol and Klingelhutz, 2013).
Retaining differentiating keratinocytes in a DNA synthesis-
competent state is key to the HPV life cycle. High-risk alpha
HPV E7 proteins target the retinoblastoma tumor suppressor
pRB for proteasomal degradation. This causes aberrant, persis-
tent S phase entry, thereby sustaining proliferative signaling.
Degradation of pRB also blunts the oncogene-induced senes-
cence response that is triggered by E7 expression and is
signaled by the CDK4/CDK6 inhibitor p16INK4A. Hence pRB
degradation also serves to evade growth suppressors. Degrada-
tion of pRB and uncontrolled S phase entry leads to p53 tumor
suppressor activation, which triggers apoptosis. To resist cell
death, high-risk HPV E6 proteins target p53 for degradation
Figure 3. Hallmarks of Cancer Analysis of
HPV-Associated Cervical Carcinogenesis
(A) High-risk HPV infections can give rise to low-
grade dysplasia (also referred to as cervical intra-
epithelial neoplasia 1 [CIN1]), which can progress to
high-grade dysplasia (also referred to as CIN2/3).
Many of these lesions spontaneously regress, pre-
sumably because of immune clearance by the host.
These lesions contain episomal HPV genomes, and
expression of the viral genes is tightly controlled by
the interplay of cellular and viral factors. Malignant
progression to invasive cervical cancer is often a very
slow process, and cervical cancers can arise years
or decades after the initial infection. Cervical
carcinomas frequently contain integrated HPV se-
quences. Expression of the viral E2 transcriptional
repressor is generally lost upon viral genome inte-
gration, resulting in dysregulated viral gene expres-
sion from the viral long control region (LCR). HPV E6
and E7 are consistently expressed even after
genome integration, and expression of these pro-
teins is necessary for the maintenance of the trans-
formed phenotype. See text for detail.
(B) High-risk HPV proteins target almost the entire
spectrum of the Cancer Hallmarks. HPV proteins that
affect each hallmark are indicated within boxes
around the wheel. See text for details.
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addition, the HPV E6 protein stimulates telomerase expression
and activity, thereby enabling replicative immortality (McLaugh-
lin-Drubin et al., 2012; Moody and Laimins, 2010).
High-risk HPVs can establish long-term persistent infection of
epithelial cells, therefore successfully avoiding immune destruc-
tion. E6 and E7 can each hinder innate immunity by inhibiting IFN
signaling (Roman and Munger, 2013; Vande Pol and Klingelhutz,
2013), and E5 proteins can downregulate MHC class I expres-
sion. Inflammation has been linked to HPV-associated cancers
but it is unknown whether and/or how HPVs may trigger inflam-
mation and/or whether inflammation may be tumor promoting or
antitumorigenic in the context of an HPV infection. E6 and E7
each contribute to epithelial-to-mesenchymal transition (EMT),
a key step in activating invasion and metastasis (Duffy et al.,
2003; Hellner et al., 2009). Moreover, E7 has been reported to
induce angiogenesis (Chen et al., 2007), and E6 and E7 also
deregulate cellular energetics. E7 causes the Warburg effect, a
shift of the standard oxidative phosphorylation-based meta-
bolism to aerobic fermentation (Zwerschke et al., 1999), and
E6 proteins activate mTORC1 signaling by prolonging receptor
protein tyrosine kinase signaling, thereby keeping cells ‘‘bliss-
fully ignorant’’ regarding their energetic states (Spangle andCell Host & MicrobeMunger, 2013). This is thought to ensure
that cellular enzymes and metabolites
necessary for viral genome synthesis are
available in differentiated, presumably
growth factor-depleted epithelial cells.
HPV16 E6/E7 can immortalize primary
human epithelial cells. The resulting cell
lines are nontumorigenic, but oncogenic
clones emerge after prolonged passaging,
and they show evidence of chromosomal
abnormalities. The high-risk HPV E6 and
E7 proteins actively contribute to this pro-cess by inducing genome instability and mutation. For E6 this
has been linked to p53 inactivation, and for E7 induction of
genomic instability is a consequence of deregulation of multiple
cellular pathways. Significantly, high-risk HPV E7 proteins cause
aberrant centrosome synthesis, giving rise tomultipolar mitoses,
which are a known hallmark of high-risk HPV-associated lesions
and cancers (Mu¨nger et al., 2006). How induction of genomic
instability may be linked to the viral life cycle is unknown,
although recent studies have shown that cellular DNA repair
mechanisms play a central role in papillomavirus genome syn-
thesis (Moody and Laimins, 2009).
HPV Multistep Carcinogenesis
Although the replication strategy of HPVs requires modulation of
cellular pathways that impinge on multiple cancer hallmarks
(Figure 3B), expression of the viral transforming proteins is tightly
controlled during normal productive HPV infections, and infected
cells only rarely undergomalignant transformation. Dysregulated
HPV E6 and E7 expression as a consequence of integration of
viral sequences into the host genome or due to epigenetic
alterations of the viral genome, however, puts cells at a higher
risk for undergoing oncogenic transformation (Figure 3A). The
ability of the E6 and E7 proteins to induce genomic instability,
thus accelerating the establishment and expansion of cells15, March 12, 2014 ª2014 Elsevier Inc. 271
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the oncogenic activities of the high-risk HPVs.
Hepatitis B Virus and Hepatitis C Virus: Direct and
Inflammation-Mediated Hepatocellular Carcinogenesis
HBV and HCV are major etiological agents of hepatocellular
carcinoma (HCC). HCC is the fifth most prevalent tumor type
worldwide and the third leading cause of cancer deaths (de Mar-
tel et al., 2012). Both viruses establish chronic infections, and
when accompanied by inflammation of the liver (hepatitis), hepa-
tocellular destruction triggers regeneration and scarring
(fibrosis), which can evolve into cirrhosis and HCC.
Molecular Mechanisms of Viral Hepatocarcinogenesis
The pathogenesis of HCC is a combination of direct and indirect
mechanisms, which results from chronic oxidative damage
that promotes the development of mutations. HBV-encoded X
antigen (HBx) and HCV-encoded core, nonstructural protein 5A
(NS5A) and NS3 directly promote HCC by altering host gene
expression, while immune-mediated inflammation contributes
indirectly to tumorigenesis. Although HBV and HCV contribute
to cancer via different mechanisms (Bre´chot, 2004), they result
in changes recognized as hallmark characteristics of cancer
(Figures 4A and 4B).
Sustained proliferative signaling indirectly promotes virus
replication through successive bouts of hepatitis, resulting in
liver damage without virus clearance. For HBV, HBx stimulates
cell-cycle entry by activating selected cyclins and cyclin-depen-
dent kinase pathways (Zemel et al., 2011) as well as pathways
such as Wnt, ras, PI3K, JAK/STAT, NF-kB, and Hedgehog that
promote survival and growth (Martin-Vilchez et al., 2011). Nu-
clear HBx regulates transcription by activating CREB, ATF-2,
ATF-3, NFAT, C/EBPb, and SMAD4 complexes and facilitates
epigenetic changes (Tian et al., 2013) that affect host cell gene
expression. HBx-mediated changes on miRNA levels modulate
oncogene and tumor suppressor gene expression (Yip et al.,
2011). HCV encodes core, NS3, and NS5A that promote liver
cell proliferation via the b-catenin pathway (Jeong et al., 2012).
HCV core promotes cyclin E and cdk2 expression. Both core
and NS3 also activate multiple signal transduction pathways
that promote cell growth.
Both HBV and HCV evade growth suppression and avoid
immune destruction by blocking apoptosis. Apoptosis is trig-
gered by virus-generated oxidative stress (intrinsic apoptosis)
and by immune-mediated apoptosis (extrinsic apoptosis).
This permits virus persistence during chronic liver disease
(CLD). HBx blocks the activation of mitochondrial antiviral
signaling protein, a key mediator of innate antiviral signaling.
Further, HBx prevents extrinsic apoptosis triggered by TNF-a,
TGF-b, and Fas by blocking caspases-8 and -3 and activating
NF-kB, the latter of which is hepatoprotective. HBx overrides
TGFb negative growth regulation, converting it to a tumor pro-
moter (Jeong et al., 2012; Zemel et al., 2011). Avoiding immune
destruction provides a survival and growth advantage for HBx-
expressing hepatocytes (Wang et al., 1991). The finding
that HBx upregulates proinflammatory cytokines (Martin-
Vilchez et al., 2011) also favors regeneration of HBx-expressing
hepatocytes, which is consistent with the observation that HBx
expression correlates with CLD (Jin et al., 2001). HCV infection
triggers innate immunity, but viral proteins block the signaling272 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.that triggers IFNb (Kumthip et al., 2012) as well as IFNa
signaling by targeting JAK/STAT (Rehermann, 2009). In addition
to avoiding immune destruction, HBV and HCV survive by
inhibiting apoptosis. For HBV, promotion or inhibition of
apoptosis is context dependent (Assrir et al., 2010). HBx
suppresses p53 by direct binding and transcriptional down-
regulation, promotes phosphorylation (inactivation) of Rb, and
downregulates several cdk inhibitors (Zemel et al., 2011). Mito-
chondria-associated HBx increases ROS. The latter, combined
with cell-cycle progression, increases the risk for the appear-
ance and propagation of mutations (Zemel et al., 2011). In
cases where HBx appears to promote apoptosis, this may
reflect a cellular response to inappropriate growth signaling
triggered by HBx (Feitelson et al., 2005). For HCV, core and
NS3 inactivate multiple tumor suppressors (Bre´chot, 2004;
Zemel et al., 2011). HCV core blocks immune-mediated
apoptosis by inhibiting caspase-8. NS5A binding to cellular
signaling molecules suppresses immune responses, tumor
suppressors, and apoptosis. HCV transgenic mice are resistant
to Fas-mediated apoptosis by blocking multiple caspases (Ze-
mel et al., 2011). Both HBV and HCV upregulate miR-181,
which promotes the appearance of ‘‘stemness’’ markers in
HCC (Jeong et al., 2012).
Replicative immortality is another cancer hallmark influenced
by HBV and HCV. The HBx gene has been found integrated
near the human telomerase reverse transcriptase (hTERT)
gene, resulting in overexpression of hTERT, which is also a
transcriptional target for HBx (Feitelson and Lee, 2007). For
HCV, stable transfection of human hepatocytes with HCV core
promoted dedifferentiation, continuous growth, and upregulated
expression of telomerase, which can promote immortalization
(Ray et al., 2000).
HBV and HCV are known to promote pathways that induce
angiogenesis. In HBV carriers, cirrhotic nodules are often hypox-
ic, and most are strongly positive for HBx. HBx may promote
survival and growth by transcriptionally activating and stabilizing
hypoxia-inducible factor 1a (HIF1a) (Yoo et al., 2003). HIF1a
transcriptionally activates angiopoietin-2 (Ang-2) and vascular
endothelial growth factor (VEGF) (Martin-Vilchez et al., 2011).
HBx upregulates matrix metalloproteinases (MMPs) that digest
the fibrous capsules of early tumors, resulting in increased
angiogenesis and metastasis. Thus, HBx promotes the cellular
response to hypoxia and stimulates angiogenesis. HCV pro-
motes angiogenesis by generating ROS, which activates multi-
ple signaling pathways that stabilize HIF1a. In both HBV and
HCV infections, fibrogenesis stimulated angiogenesis, because
CLD is characterized by elevated levels of the angiogenic cyto-
kines, including VEGF (Vrancken et al., 2012), which may be an
important therapeutic target that could delay the onset and/or
progression of HCC.
Invasion and metastases are important in malignant progres-
sion of HCC, and the elevated expression of hepatocyte growth
factor (HGF) receptor, c-met, can lead to scattering, angiogen-
esis, proliferation, enhanced cell motility, invasion, and metas-
tasis. HBx may promote c-met expression (Xie et al., 2010),
but it is not clear whether this occurs with HCV. HBx also pro-
motes invasion and metastasis by stimulating expression of
MMPs, which degrade fibrous capsules around tumor nodules
(Zemel et al., 2011). HCV core abrogates TGFb-dependent
Figure 4. Hallmarks of Cancer Activation during the Progression of HBV and HCV Infection to HCC
(A and B) The diagram shows hallmarks activation during HBV infection, primarily by the viral HBx protein (A), and during HCV infection, mainly by the viral core,
NS5A, and NS3 proteins (B). The host mediators that contribute to each of the hallmarks are indicated in black text boxes. Hallmarks achieved early (left wheel)
and late (right wheel) over the course of HBV- and HCV-associated HCC pathogenesis are shown for each panel. The major steps in the progression of HBV and
HCV infection to HCC are shown at the bottom of each panel. The progression of these steps is indicated by increasingly darker tan-colored arrows. Please see
the text for additional details.
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resulting in EMT and tumor invasion.
Tumor-promoting inflammation is critical to HCC develop-
ment. ROS generated in this context promotes a micro-
environment conducive to mutagenesis, tumor developmentand survival. CLD results in tissue damage, regeneration,
fibrosis, and eventually hypoxia. In hypoxia, stem-like and pro-
genitor cells survive and expand (Keith and Simon, 2007) and
may form carcinoma in situ. In HCV, NS5A promotes expression
of the stem cell factor Nanog (Machida et al., 2012). For HBV,Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 273
Cell Host & Microbe
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ness’’-promoting factors (Arzumanyan et al., 2011).
Genome instability andmutation contribute to HBV- and HCV-
driven tumor initiation and progression. During CLD, hepatocel-
lular regeneration is accompanied by integration of HBV DNA
fragments most often spanning the X gene. Although integration
is common and appears random, there is clustering near or
within fragile sites and other cancer-associated regions that
are prone to genetic instability (Feitelson and Lee, 2007). cis-
acting mechanisms in HCC have been reported, although the
only host gene with integration events in tumors from different
patients is hTERT (Feitelson and Lee, 2007). Many integration
events encode functional HBx (Kew, 2011). HBx inactivates
p53, thereby compromising genome integrity (Matsuda and
Ichida, 2009). HBx also inhibits DNA damage-binding protein 1
(DDB1) in nucleotide excision repair. HBx promotes the appear-
ance of multinucleated cells, chromosomal rearrangement, and
micronuclei formation (Martin-Vilchez et al., 2011). HBx interacts
with proteins that regulate centrosomal integrity, such as chro-
mosome maintenance region 1 (Crm1) and HBXIP (Martin-Vil-
chez et al., 2011). Crm1 transports HBx into the cytoplasm, but
when HBx inactivates Crm1, HBx accumulates in the nucleus
where it alters host gene expression that promotes cell growth.
HBXIP binding to HBx results in excessive centrosome replica-
tion, tripolar and multipolar spindles, and subsequent aberrant
chromosome segregation. Thus, HBx is centrally involved in
genome instability.
DNA repair and apoptosis are also regulated by poly(ADP-
ribose) polymerase 1 (PARP-1) (Langelier and Pascal, 2013).
HBx stabilizes PARP, which protects infected cells from
apoptosis. HCV NS5A stabilizes PARP-1 by blocking caspase-
3-mediated cleavage (Zemel et al., 2011). PARP-1 cleavage is
also accelerated by HCV (Zhao et al., 2012). The latter may
permit the propagation of mutations and promote genetic insta-
bility in HCV-infected cells.
Deregulating cellular energetics permits dysplastic cells and
cells in in situ tumors to survive and grow. In aerobic glycolysis,
where pyruvate is converted into lactate, the latter is used to
accelerate biosynthesis for growth in the absence of oxidative
phosphorylation. The underlying switch (Warburg effect) involves
crosstalk between metabolic pathways in the mitochondria and
epigenetic mechanisms in the nucleus (Martinez-Pastor et al.,
2013). Protein acetylation derives from the intracellular pool of
acetyl-CoA,most ofwhichderives fromcitrate (in theKrebscycle)
in mitochondria. HBx and HCV core in mitochondria may affect
the intracellular citrate levels by triggeringchronicoxidative stress
that disrupts membrane potential (mtDJ) and organelle function
(Brault et al., 2013). This may reduce the levels of citrate that are
available for conversion to acetyl-CoA and thus for epigenetic
modification of chromatin through protein acetylation. HBx and
HCV activate histone deacetylase 1 (HDAC1) and upregulated
metastasis-associated protein 1 (MTA-1) (Yoo et al., 2003), both
of which contribute to HCC. HCV core promoted steatosis, and
HBx induced b-catenin, in part, by attenuating expression of
SIRT1, an NAD-dependent histone deacetylase (Srisuttee et al.,
2012). When glucose is plentiful, NAD is converted to NADH
and SIRT1 is inhibited, so these viruses may mimic conditions
that promote tumor cell growth via epigenetic modification of
host gene expression. HBV and HCV also upregulate DNAmeth-274 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.yltransferases (DNMTs),whichmayblock theexpressionof tumor
suppressor genes that are methylated in HCC (Tian et al., 2013).
Human T Cell Lymphotropic Virus-1: Causal Agent of
Adult T Cell Leukemia/Lymphoma
HTLV-1, the first described human lymphotropic retrovirus, is the
etiologic agent for adult T cell leukemia/lymphoma (ATL), an
incurable malignancy of mature CD4+ T cells, which is endemic
to Japan and certain areas of Africa and Central and South
America (Cesarman and Mesri, 2007; Matsuoka and Jeang,
2007; Yoshida, 2001). HTLV-1-driven oncogenesis is a two-
step process: a Tax-dependent stage, in which the Tax transac-
tivator induces T cell proliferation that subsequently switches to
a Tax-independent stage. In this second stage, Tax is repressed
or deleted, and thus the oncogenic process is driven by the
HTLV-1 bZip (HBZ) protein and its RNA, together with host onco-
genic alterations (Matsuoka and Jeang, 2007) (Figure 5).
Activation of Cancer Hallmarks by HTLV-1
Tax. Tax is a pleiotropic viral oncoprotein that induces T cell
expansion by activating cell proliferation and survival pathways
such as NF-kB, PI3K-AKT, and CREB (Cesarman and Mesri,
2007; Matsuoka and Jeang, 2007; Yoshida, 2001). Tax activates
the IKK complex by directly interacting with NEMO through a
mechanism that involves Tax ubiquitination via Ubc13 (Shem-
bade et al., 2007) and by blocking PP2A inactivation of IKK
signaling. In T cells NF-kB activates genes related to T cell pro-
liferation, growth, and survival such as REL, MYC, and the
ligand and the receptor for the T cell growth factor IL-2, leading
to an IL-2 autocrine loop (Leung and Nabel, 1988; Maruyama
et al., 1987). This, together with hTERT activation, which enables
replicative immortality, is thought to mediate Tax-induced
immortalization (Grassmann et al., 2005). Tax also activates
CREB-mediated transcription (Kwok et al., 1996) via a PKA-
independent pathway and regulates CBP/p300. Tax activates
the PI3K-AKT prosurvival and growth pathway (Matsuoka and
Jeang, 2007). Tax oncogenicity is evidenced by its ability to
promote cell-cycle entry by CDK activation, its ability to inhibit
p53 through modulation of p300/CBP or via the phosphatase
Wip-1 (Zane et al., 2012), and by the disc large (DLG) tumor
suppressor (Grassmann et al., 2005; Matsuoka and Jeang,
2007). Furthermore, Tax inhibits the DDR and interacts with the
mitotic apparatus (Ching et al., 2006), causing chromosomal
aberrations and genomic instability, thus increasing the likeli-
hood of acquiring somatic oncogenic alterations (Grassmann
et al., 2005; Matsuoka and Jeang, 2007).
HBZ. Although many HTLV-1 genomes are deleted in their 50
end, all of them are intact in the 30 LTR from where they are
able to stably transcribe HBZ mRNA throughout the process of
infection and transformation (Matsuoka and Jeang, 2007; Satou
et al., 2006). HBZ is also able to activate cancer hallmarks and
thus to partially compensate for Tax downregulation. HBZ pro-
tein and RNA appear to be critical for supporting the survival
and immune evasion of ATL cells (Matsuoka and Jeang, 2007;
Satou et al., 2006). In addition to activating transcription of
JUND, JUN, and ATF prosurvival genes, the HBZ RNA may be
able to directly activate cell proliferation (Satou et al., 2006) by
promoting transcription of the cell-cycle promoter E2F. HBZ
also activates hTERT expression, supporting replicative immor-
tality (Matsuoka and Jeang, 2007).
Figure 5. Hallmarks of Cancer Analysis for HTLV-1-Induced Adult T Cell Leukemia/Lymphoma
Tax activation of survival and proliferation hallmarks in HTLV-1-infected T cells causes polyclonal expansion of infected cells. However, since Tax is immuno-
genic, host CTLs select for infected cells with downregulated or deleted Tax. After a prolonged asymptomatic period of 20–40 years, which involves acquisition of
host mutations, immortalization, and clonal expansion, adult T cell leukemia/lymphoma (ATL) cells emerge in approximately 5% of infected individuals. Tax
functions are compensated by HZB-mediated hallmark activation and by host mutations such as p16INK4A and p53. Most HTLV-1-infected individuals remain
asymptomatic carriers.
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Tax expression induces polyclonal proliferation of HTLV-1-in-
fected T cells. However, Tax is a target of host CTLs (Matsuoka
and Jeang, 2007). Thus, cells that lose Tax expression by
silencing or deletion will evade immune elimination and be favor-
ably selected (Figure 5). Survival of Tax-negative cells is sup-
ported by HTLV-1 HBZ protein and RNA and by host somatic
mutations (Matsuoka and Jeang, 2007), all of which lead to
immortalization. This preneoplastic state sets the stage for
further acquisition of somatic host alterations including deletion
or mutations of the CDKN2A/p16INK4A and TP53 tumor suppres-
sor genes (Sato et al., 2010; Uchida et al., 1998) and chromo-
somal aberrations, generally correlating with tumor progression,
and eventually resulting in T cell malignant transformation (Mat-
suoka and Jeang, 2007). Consistent with Tax-expressing HTLV-
1-infected cells being controlled by T cell responses, known
cofactors for ATL development in HTLV-1-infected individuals
are related to the individual’s ability to control HTLV-1 infection,
including immune status and coinfection with certain parasites
(Matsuoka and Jeang, 2007).
Kaposi’s Sarcoma Herpesvirus: Tumorigenesis by
Classic and Paracrine Oncogenesis
KSHV or human herpesvirus-8 (HHV-8) is a g2-herpesvirus that
is the causal agent of Kaposi’s sarcoma (KS) (Chang et al.,
1994; reviewed in Ganem, 2010; Mesri et al., 2010). KS is char-
acterized by the proliferation of infected spindle cells of vascular
and lymphatic endothelial origin, accompanied by intense angio-
genesis with erythrocyte extravasation and inflammatory infiltra-
tion (Ganem, 2010; Mesri et al., 2010). KSHV can infect a varietyof cells including endothelial lineage, monocytes, and B cells.
KSHV encodes many oncogenic viral homologs of host proteins
with the potential to drive cell survival, proliferation, immune
evasion, and angiogenesis (Coscoy, 2007; Ganem, 2010; Mesri
et al., 2010). Similar to other herpesviruses, such as EBV, dis-
cussed above, KSHV can undergo latent or lytic stages of repli-
cation. Latency is a state whereby KSHV replicates along with
the host by expressing KSHV latency-associated nuclear anti-
gen (LANA), which tethers the KSHV episome to the host chro-
mosome, thus assuring its maintenance and segregation during
host cell division. In the KSHV lytic cycle, the virus expresses the
full viral program necessary for replication and assembly of
infectious virus with cytopathic cell lysis (Ganem, 2010; Mesri
et al., 2010). Both KSHV lytic and latent gene expression pro-
grams are thought to be necessary for KS development, and
KS lesions contain mostly latently infected cells with a variable
percentage of lytically infected cells (Ganem, 2010; Mesri
et al., 2010). The potential contributions of individual latent and
lytic KSHV gene products to KS and to specific cancer hallmarks
are discussed below and depicted in Figure 6.
Cancer Hallmarks Activation during Latent KSHV
Infection
KSHV latent transcripts includegenesandmiRNAs that favor viral
persistence and replicationwhile promoting host cell proliferation
and survival. LANA and v-cyclin affect cell-cycle checkpoint
mediators. LANA inhibits both the p53 (Friborg et al., 1999) and
the pRB tumor suppressor pathways (Radkov et al., 2000), thus
allowing the infected cell to become insensitive to antigrowth sig-
nals, avoiding cell-cycle arrest and promoting genetic instability
(Si and Robertson, 2006). KSHV promotes cell proliferation viaCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 275
Figure 6. Hallmarks of Cancer Analysis for Kaposi’s Sarcoma Pathogenesis Based on the Paracrine Oncogenesis Hypothesis
KSHV infections could be either latent or lytic. Latently infected cells express the LANA transcript and the KSHV miRNA. Although these genes can activate KS
cancer hallmarks, they are insufficient to transform the cell and to induce the characteristic KS angiogenic phenotype. Lytic infected cells, on the other hand,
express viral genes that make them highly angiogenic and inflammatory. However, these cells are under tighter immune control and are doomed for cytopathic
death. In immunosuppressed individuals and those with AIDS, lytic infection is more permissible, and it can combine with latently infected cells to form tumors via
the mechanism of paracrine oncogenesis (see text for details). At bottom left is a schematic representation of a KS tumor showing latently infected cells (filled in
green), lytically infected cells (filled in red), blood vessels (unfilled in red), and paracrine effects (depicted as red arrows). Within the boxes around the wheel, latent
viral genes are in green, lytic viral genes are in red, and host genes are in black. The figure is not a strict representation of experimental data, but a compilation of
published information analyzed in the context of the Hallmarks of Cancer and the paracrine oncogenesis hypothesis. Genes chosen for hallmarks activation
represent one of the available examples and are based on published data with preference for tumor-relevant systems where available. Filled portions of the
hallmark pie are used to represent stronger or well-documented hallmark activation. Empty portions represent weaker effects or lack of activation/evidence. See
text for explanations and references.
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(Swanton et al., 1997), that is able to directly downregulate the
p27KIP1 CDK inhibitor (Ellis et al., 1999; Sarek et al., 2006).
LANA antagonizes growth-inhibitoryWNT signaling by stabilizing
b-catenin through sequestration of its negative regulator GSK-
3b, upregulating via this and other pathways the expression of
MYC (Fujimuro et al., 2003). Furthermore, LANA targets the
ubiquitin ligase Sel10 to stabilize the Notch proto-oncogene,
leading to cell proliferation (Lan et al., 2007). Thus, through the
concerted activity of LANA and v-cyclin, latently infected cells
become self-sufficient in growth signals and proliferate.
Latent KSHV evades apoptosis by promoting NF-kB signaling
through different mechanisms. The FLICE/caspase-8-inhibitory276 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.protein (vFLIP) is a potent constitutive activator of NF-kB anti-
apoptotic signaling that is critical for survival of latently infected
cells (Guasparri et al., 2004). In addition, KSHV-encoded
miRNAs promote survival and tumorigenesis by targeting regula-
tory members of the NF-kB pathway (Zhu et al., 2013).
LANA supports a proangiogenic program by stabilizing the
VEGF transcription factor hypoxia-inducible factor 1a (HIF1a)
via targeting its ubiquitin ligase, the von Hippel- Lindau (VHL) tu-
mor suppressor, for degradation (Cai et al., 2006). In addition,
vFLIP-activation of NF-kB leads to the induction and secretion
of proangiogenic cytokines such as IL-6 (Grossmann et al.,
2006). The viralmiRNAmiRK1-5 has been reported to downregu-
late the antiangiogenic protein thrombospondin-1 (TSP-1)
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esis. LANA can increase the lifespan of human umbilical vein
endothelial cells and is an activator of hTERT expression, which
can confer cells with limitless replicative potential (Verma et al.,
2004).
Metabolic profiling of KSHV-infected cells indicates that the
virus reprograms the metabolism of host cell to resemble that
of cancer cells (Delgado et al., 2012). Specifically, KSHV infec-
tion shifts endothelial cells toward aerobic glycolysis and lactic
acid production while decreasing oxygen consumption, thus
inducing the Warburg effect, an enabling metabolic character-
istic of tumor cells (Delgado et al., 2010).
vFLIP-activated NF-kB signaling drives inflammation via over-
expression of many cytokines and chemokines implicated in KS
pathogenesis (Grossmann et al., 2006), while viral Kaposin B can
upregulate cytokine mRNA levels by activating a kinase that
inhibits the mRNA decay pathway (McCormick and Ganem,
2005). Interestingly, KSHV upregulation of inflammatory media-
tors such as COX-2 and its metabolites were found to play a
role in maintenance of viral latency through LANA upregulation
(George Paul et al., 2010). In addition to being less immunogenic,
latently infected cells can evade the immune response by resist-
ing Fas-induced apoptosis through vFLIP-induced activation of
NF-kB, which leads to upregulation of antiapoptotic members
of the Bcl-2 family (Guasparri et al., 2004).
Cancer Hallmarks Activation during Lytic KSHV Infection
During lytic infection, KSHV expresses the full replication
program to produce new virions. Several of these gene products
including vGPCR, vIRF1, and vBCL2 are viral homologs of host
signaling and growth regulators. The KSHV lytic program in-
duces cancer hallmarks through the expression of genes that
favor viral replication by affecting the DDR, reprogramming
metabolism, promoting survival, andmediating immune evasion.
KSHV lytic genes also induce host responses for recruiting
cells of the endothelial andmonocytic lineages and thus promote
angiogenesis and inflammation, which are characteristic hall-
marks of KS (Figure 6).
Insensitivity to Antigrowth Signals. A viral homolog of the IFN-
inducible factor, vIRF-1, inhibits the tumor suppressor p53 via
interaction with its coactivator, p300/CBP, promoting its mono-
ubiquitination and delocalization to the cytoplasm (Nakamura
et al., 2001).
Self-Sufficiency in Growth Signals. KSHV encodes a constitu-
tively active G protein-coupled receptor homolog (vGPCR) of
the angiogenic chemokines IL-8 and Groa receptors. vGPCR,
the ITAM-like sequence bearing K1 protein, and ORF45 all
constitutively induce ERK and PI3K/AKT/mTOR cascades
(Bais et al., 2003; Chang and Ganem, 2013; Wang et al., 2006).
vGPCR activates secretion of VEGF, IL-6, and PDGF (Jensen
et al., 2005), which, together with the vIL-6 viral chemokine (or
virokine) (Nicholas et al., 1997), are autocrine growth factors
that can also drive latent cell proliferation by paracrine mecha-
nisms (Montaner et al., 2006).
Evading Apoptosis. vGPCR activates PI3K/AKT and NF-kB
antiapoptotic pathways that promote endothelial cell survival
(Bais et al., 2003). In addition to reducing p53-driven cell death,
vIRF-1 can prevent apoptosis during viral replication by direct
inhibition of proapoptotic BH3 domain-containing proteins
such as BIM (Choi and Nicholas, 2010).Genome Instability. vIRF-1 inhibits ATM activation of p53 to
suppress DNA damage-induced apoptosis, a response that
can lead to accumulation of mutations and genomic instability
(Shin et al., 2006). vGPCR activates ROS production via
RAC1 activation of NADPH-oxidase (Ma et al., 2013). ROS can
cause oxidative DNA damage leading to increased mutation
rate and accumulation of chromosomal alterations.
Sustained Angiogenesis. Prominent angiogenesis is a typical
characteristic of KS. Several lytic genes have the potential to
cause an angiogenic switch in infected cells. vGPCR activates
VEGF expression and secretion (Bais et al., 1998) via MAPK
phosphorylation of HIF1a (Sodhi et al., 2000) and through
activation of the PI3K-AKT-mTORC1 pathway (Sodhi et al.,
2006). vGCPR is also capable of upregulating numerous proan-
giogenic factors such as PDGF, Angiopoietin-2 (ANGPT2), and
IL-6 (Jensen et al., 2005). vGPCR is a potent angiogenic onco-
gene able to induce angioproliferative KS-like lesions in several
transgenic mouse models (Jensen et al., 2005; Montaner et al.,
2003), and it was shown to be necessary for KSHV tumorigenesis
and angiogenesis (Mutlu et al., 2007). Other angiogenic lytic
genes are K1, which activates secretion of VEGF, and MMP-9
(Wang et al., 2004), which together with vGPCR mediates endo-
thelial-to-mesenchymal transition (EnMT) that may favor cell
invasion and metastasis (Cheng et al., 2011). Virokines such as
vMIP-I, vMIP-II, and vMIP-III (Stine et al., 2000) (also referred
to as vCCLs) and vIL-6 (Aoki et al., 1999) have also been shown
to have proangiogenic properties in several experimental sys-
tems.
Limitless Replicative Potential/Immortalization. vGPCR-medi-
ated autocrine activation of VEGF-R2/KDR can immortalize
human EC via alternative lengthening of telomeres (ALT) (Bais
et al., 2003). Ectopic expression of K1 in endothelial cells has
also been reported to cause cellular immortalization (Wang
et al., 2004).
Metabolic Reprogramming. Several lytic proteins including
vGPCR, K1, and ORF45 activate the master metabolic regulator
mTORC1 (Chang and Ganem, 2013; Sodhi et al., 2006; Wang
et al., 2006). mTORC1 activation drives protein and nucleotide
synthesis needed for viral replication by switching glucosemeta-
bolism toward aerobic glycolysis, an enabling characteristic of
proliferative cancer cells. ORF45 activates mTORC1 via ERK2/
RSK (Chang andGanem, 2013) while vGPCR activates mTORC1
by directly triggering the PI3K-AKT pathway and through para-
crine interactions by growth factors such as VEGF and PDGF
that act on mTORC1-activating receptors (Sodhi et al., 2006).
The viral K3 ubiquitin ligase may induce glucose metabolic re-
programming in lytically infected cells by affecting stability and
signaling via receptor tyrosine kinases (Karki et al., 2011).
Inflammation. vGPCR induces inflammatory signaling and
cytokine secretion (Bais et al., 1998; Sodhi et al., 2006). KSHV-
encoded virokines such as vMIP-III can chemoattract inflamma-
tory cells (Stine et al., 2000). K15, a predicted transmembrane
viral protein, can promote inflammatory signaling via JNK and
NF-kB signaling, leading to secretion of various chemokines
and cytokines (Brinkmann et al., 2007).
Immune Evasion. Lytic KSHV expresses many immune-regu-
latory genes, including vIRF-1 to vIRF-4, which display variable
specificities for inhibition of the type I IFN response (Offermann,
2007). ORF63 encodes for a viral homolog of human NLRP1,Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 277
Table 1. Therapeutic and Preventive Approaches Successfully Used to Prevent and Target Oncoviral Infections or Their Cancer-
Associated Hallmarks
Virus Cancer Intervention or Drug Target Hallmark or Process
Pharmacological Approaches
HBV/HCV HCC Sorafenib VEGFR-2, PDGFR, Raf Angiogenesis, cell proliferation
HBV Viral CLD leading to HCC Nucleoside analogs, IFN Viral polymerase, protein translation Chronic infection
HCV Viral CLD leading to HCC Ribavirin, IFN, protease
inhibitors
Viral replication, protein translation Chronic infection
KSHV Transplant KS, AIDS-KS Rapamycin mTORC1 Angiogenesis, cell proliferation
AIDS-KS Imatinib PDGFR, c-kit Cell proliferation
HTLV-1 ATL AZT + aIFN NF-kB Survival
EBV NHL Butyrate + GCV HDAC, vTK, DNA pol Cell proliferation, survival
Immunoprophylaxis and Immunotherapy
EBV PTLD EBV-specific CTL Lat III-infected cells Survival, immune evasion
HPV CxCa, HNCC L1 VLP vaccine Infection Infection
HBV HCC HBsAg VLP vaccine Infection Infection
Abbreviations not found in the main text: CxCa, cervical carcinoma; VLP, viral-like particle; HNCC, head and neck cancer, vTK, viral thymidine kinase.
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2011). Similar to other herpesviruses, KSHV has evolved unique
abilities to downregulate immune-recognition receptors. They
include the K3 and K5 ubiquitin ligases that are able to down-
regulate MHC-I, ICAM, and NK receptors (Cadwell and Coscoy,
2005; Coscoy, 2007).
Mechanisms of KSHV-Induced Oncogenesis
As outlined above, KSHV’s comprehensive oncogenic arsenal
conveys all cancer hallmarks. Yet the ability of KSHV to cause
cancer is limited to four clinically defined populations: HIV/
AIDS patients (epidemic or AIDS-associated KS), immunosup-
pressed individuals (transplant KS), people living in geographical
areas in sub-Saharan Africa (endemic KS), and elderly individ-
uals of Mediterranean or Azhkenazi origin (classic KS) (Ganem,
2010; Mesri et al., 2010). To explain the high incidence of KS in
HIV/AIDS patients, HIV-1 and immune-related mechanisms
have been proposed. Changes in cytokine profiles that are
characteristic of HIV/AIDS-associated immune activation as
well as the presence of HIV-1 Tat can favor KS development
via increased KSHV lytic reactivation and also by direct angio-
genesis mechanisms (Aoki and Tosato, 2007). During AIDS,
decrease in CD4+ T helper cells hampers immune control of
KSHV-infected cells. Lytic patterns of expression include more
oncogenic genes (Figure 6), but they are alsomore immunogenic
(Ganem, 2010; Mesri et al., 2010). Both CTLs and a type of
suppressor T cells are able to either eliminate or suppress lytic
infection (Myoung and Ganem, 2011). Thus, in immunocompe-
tent hosts, lytic KSHV-infected cells are suppressed by the
immune system. In immunosuppressed patients, however,
KSHV-infected cells are not subject to immune clearance, thus
allowing KSHV to express its full oncogenic repertoire, including
genes able to induce characteristic KS hallmarks such as angio-
genesis and inflammation. Latently infected cells that also ex-
press the oncogenic early lytic genes but would not complete
the lytic cycle, referred to as abortive lytic replication (Bais
et al., 2003), may become progressively transformed and ac-
quire somatic oncogenic alterations that would allow the in-
fected cells to switch back to less immunogenic latent forms,278 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.similar to what has been discussed for HTLV-1 and for EBV Lat
I cancers. A second scenario would have to take into account
the paradoxical fact that while KSHV latently infected cells,
which are amajority of the spindle cells in KS lesions, are not fully
transformed, lytic infection where KSHV angiogenic oncogenes
are expressed is cytopathic, and thus lytically infected cells
cannot be a stable part of the transformed state. A ‘‘paracrine
oncogenesis’’ hypothesis has been developed that is based on
the occurrence in KS lesions of either lytically infected cells or
latently infected cells expressing lytic genes (Bais et al., 2003;
Chang andGanem, 2013;Montaner et al., 2003) (Figure 6). These
cells express KSHV genes such as vGPCR, K1, and ORF45,
which stimulate the production of host cytokines and angiogen-
esis growth factors, which, in concert with virokines vIL-6 and
vMIPs/vCCLs, will stimulate angiogenesis and support latently
infected cell proliferation (Figure 6) (Mesri et al., 2010). Hence,
the full KSHV-induced oncogenic complement enabling the
acquisition of all cancer hallmarks for KS tumor formation may
be achieved by a paracrine connection between latently and
lytically infected cells (Figure 6). This is supported by laboratory
findings that cells expressing KSHV lytic genes enable tumorige-
nicity of latent KSHV genes via paracrinemechanisms (Montaner
et al., 2006). This model also accounts for the higher incidence of
KS in immunosuppressed and HIV/AIDS patients. Clinical find-
ings consistent with the necessity of lytically infected cells for
AIDS-KS tumor formation and the role of the immune system in
their control include the steep decline in AIDS-KS incidence
since ART implementation, the anti-AIDS-KS response to ART
upon immune reconstitution, and the observation that some anti-
viral drugs targeting KSHV lytic replication were able to prevent
AIDS-KS (reviewed in Casper, 2011; Mesri et al., 2010).
Preventing and Targeting Viral Oncogenesis in the
Clinical Setting
Virus-induced cancers are amenable to immunoprophylaxis by
vaccines (Schiller and Lowy, 2010). Further, viral oncogenes
constitute attractive and sometimes druggable nonhost targets.
This is exemplified by the major success in vaccinating against
Cell Host & Microbe
ReviewHBV, the promise of prophylactic HPV vaccines (Schiller and
Lowy, 2010), as well as the new-generation nucleoside analogs
to treat HCV. Current clinical efforts in preventing or treating vi-
rus-induced cancers are a combination of antiviral agents,
agents that induce virus-related cytotoxicity events, agents
that target virus-induced cancer hallmarks, and agents that are
used to successfully treat cancers with similar histological clas-
sification but of nonviral etiology. Table 1 summarizes some of
the most promising and successful approaches that are either
FDA approved or have already been clinically tested. Despite
these major successes, the treatment of virus-induced cancers
remains challenging. Major obstacles are the limited availability
of validated preclinical animal models for some virally induced
cancers and the complexity of simultaneously targeting the viral
and the host oncogenome, which on one hand may increase the
number of potential therapeutic targets but also provides two
sources of potential resistance to therapy.
Conclusion
Human viral cancers are pathobiological consequences of infec-
tion with viruses that evolved powerful mechanisms to persist
and replicate through deregulation of host oncogenic pathways,
conveying cancer hallmarks to the infected cell. The six major
human oncoviruses are able to target many of these pathways.
Natural barriers to viral oncogenesis are the immune response
and the innate safeguard for human cancer constituted by the
multihit nature of the carcinogenesis process, forwhich viral infec-
tion contributes only partially. Environmental and host cofactors
such as immunosuppression, genetic predisposition, or muta-
gens can each affect this delicate equilibrium and could accel-
erate the development of these cancers. The infectious nature
and long incubationperiodsofhumanviral cancersprovideunique
windows of opportunity for prevention and clinical intervention.
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